Showing 6391-6400 of 8293 results for "".
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Game Changer: Incyte’s Ruxolitinib Reverses Vitiligohttps://practicaldermatology.com/news/game-changer-incytes-ruxolitinib-reverses-vitiligo/2461392/Topical Ruxolitinib is highly effective for skin re-pigmentation in vitiligo, according to Phase III clinical trial results published in The New England Journal of Medicine. The study showed better than 75 percent improvement on face and 50 percent improvement on body fo
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB
- Thirdhand Smoke Linked to Contact Dermatitis, Psoriasishttps://practicaldermatology.com/news/thirdhand-linked-to-contact-dermatitis-psoriasis/2461389/Acute exposure to thirdhand smoke on the skin elevates biomarkers associated with the initiation of skin diseases, such as contact dermatitis and psoriasis. “We found exposure of human skin to THS initiates mechanisms of inflammatory skin disease, and elevate
- Dr. Ida Orengo Named Chair of Department of Dermatology at Baylor College of Medicinehttps://practicaldermatology.com/news/dr-ida-orengo-named-chair-of-department-of-dermatology-at-baylor-college-of-medicine/2461384/Dr. Ida Orengo has been named chair of the Department of Dermatology at Baylor College of Medicine by the College’s Board of Trustees. Her appointment is effective Oct. 17. Dr. Ore
- La Roche-Posay and the Women's Dermatologic Society Partner for Inaugural Diversity in Dermatology Fellowship at Howard Universityhttps://practicaldermatology.com/news/la-roche-posay-and-the-womens-dermatologic-society-partner-for-inaugural-diversity-in-dermatology-fellowship-at-howard-university/2461383/La Roche-Posay is partnering with the Women's Dermatologic Society (WDS) to sponsor a Fellowship in the Department of Dermatology at Howard University's College of Medicine for UIM medical students. The fellowship was created to support UIM candidates who are seeking additional clinical o
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- Hugel Resubmits Botulax BLA to FDAhttps://practicaldermatology.com/news/hugel-resubmits-botulax-bla-to-fda-1/2461380/Hugel resubmitted the BLA for its botulinum toxin called Botulax for smoothing glabellar lines to the U.S. FDA. Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) to advance into the U.S. market i
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo